Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Oncotarget|March 20, 2018
Thymoma size significantly affects the survival, metastasis and effectiveness of adjuvant therapies: a population based studyDongliang Bian, Feng Zhou, Weiguang Yang, et al.
The Annals of Thoracic Surgery|March 7, 2026
Neoadjuvant chemoimmunotherapy followed by surgery or radiotherapy for stage IIIA-B non-small cell lung cancer with bulky N2 diseaseSuyu Wang, Yifei Zhou, Shiqi Hu, et al.
Translational Lung Cancer Research|February 26, 2024
Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single centerAo Zeng, Yicheng Xiong, Jing Zhang, et al.
Cancer Immunology, Immunotherapy : CII|November 6, 2023
The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancerZiyun Shen, Meixin Teng, Lu Han, et al.
Interdisciplinary Cardiovascular and Thoracic Surgery|June 10, 2026
Adjuvant chemotherapy for resected stage-ia lung adenocarcinoma with micropapillary histologic patternYifei Zhou, Dongliang Bian, Fujun Yang, et al.
Translational Lung Cancer Research|April 18, 2025
Palliative surgery is effective in patients with EGFR-mutant lung adenocarcinoma with pleural metastasisYue Liu, Yifei Zhou, Shuangyi Li, et al.
Translational Lung Cancer Research|September 12, 2022
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysisDongliang Bian, Siming Jiang, Yicheng Xiong, et al.
BMC Medicine|July 18, 2025
Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trialShuyu Ji, Zhenxin Sheng, Dongliang Bian, et al.
Genome Medicine|March 3, 2023
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencingJunjie Hu, Lele Zhang, Haoran Xia, et al.
Nature Communications|August 3, 2023
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II studyDongliang Bian, Liangdong Sun, Junjie Hu, et al.
Pageof 4